Chartwell Investment Partners LLC Sells 57,857 Shares of Roche Holding AG (OTCMKTS:RHHBY)

Chartwell Investment Partners LLC lessened its holdings in Roche Holding AG (OTCMKTS:RHHBY) by 39.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,572 shares of the company’s stock after selling 57,857 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Roche were worth $3,511,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. AlphaMark Advisors LLC acquired a new position in shares of Roche in the third quarter valued at $149,000. GAMMA Investing LLC increased its holdings in shares of Roche by 61.5% in the second quarter. GAMMA Investing LLC now owns 5,038 shares of the company’s stock valued at $175,000 after purchasing an additional 1,919 shares during the last quarter. Verity Asset Management Inc. acquired a new position in shares of Roche in the third quarter valued at $253,000. Archer Investment Corp increased its holdings in shares of Roche by 10.6% in the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock valued at $236,000 after purchasing an additional 652 shares during the last quarter. Finally, Waldron Private Wealth LLC bought a new stake in shares of Roche in the second quarter valued at about $263,000.

Roche Stock Performance

Shares of OTCMKTS:RHHBY opened at $37.62 on Tuesday. The stock’s fifty day simple moving average is $39.38 and its two-hundred day simple moving average is $36.93. Roche Holding AG has a 1-year low of $29.20 and a 1-year high of $42.43.

Wall Street Analyst Weigh In

RHHBY has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft cut shares of Roche from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Bank of America raised shares of Roche from a “neutral” rating to a “buy” rating in a research report on Friday, September 13th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.